Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hendra and nipah virus g glycoprotein immunogenic compositions

A technology of immunogenicity and Nipah virus, applied in the direction of virus antigen components, viruses, drug combinations, etc., can solve the problems of high cost and difficulty

Inactive Publication Date: 2016-08-03
ZOETIS SERVICE LLC
View PDF12 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, since these viruses are zoonotic Biosafety Level-4 pathogens (BSL-4), it is very costly and difficult to safely produce vaccines and / or diagnostics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hendra and nipah virus g glycoprotein immunogenic compositions
  • Hendra and nipah virus g glycoprotein immunogenic compositions
  • Hendra and nipah virus g glycoprotein immunogenic compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1: Vector construct

[0078] Construct a vector to express HeVG or NiVG with missing transmembrane / cytoplasmic tail. The cloned cDNA of the full-length HeVG protein or NiVG protein was amplified by PCR to generate a fragment of about 2600 nucleotides with the HeVG protein or NiVG protein encoding the transmembrane domain / cytoplasmic tail region deletion.

[0079] The following oligonucleotide primers were synthesized to amplify HeVG. sHGS: 5'-GTCGACCACCATGCAAAATTACACCAGAACGACTGATAAT-3' (SEQ ID NO: 5). sHGAS: 5'-GTTTAAACGTCGACCAATCAACTCTCTGAACATTGGGCAGGTATC-3' (SEQ ID NO: 6).

[0080] The following oligonucleotide primers were synthesized to amplify NiVG. sNGS: 5'-CTCGAGCACCATGCAAAATTACACAAGATCAACAGACAA-3' (SEQ ID NO: 7). sNGAS: 5'-CTCGAGTAGCAGCCGGATCAAGCTTATGTACATTGCTCTGGTATC-3' (SEQ ID NO: 8).

[0081] Use Accupol DNA Polymerase (PGS Scientific Corporation (PGSScientificsCorp)) to perform all PCR reactions with the following settings: Initially 94°C for 5 minutes; ...

Embodiment 2

[0090] Example 2: Protein production of soluble G protein using CHO cells

[0091] The Chinese hamster ovary (CHO) ChK2 cells from St. Louis were thawed and transferred to a sterile 125 ml flask containing CD-CHO medium (Invitrogen) and 6mM Glutamax (Gibco), and passaged. One hour before transfection, the medium was removed and replaced with fresh ChK2 adherent medium. The pCTV927 / Hendra virus sGT1 plasmid was isolated, ethanol precipitated, and resuspended to a concentration of 0.85 μg / μL. Use Lipofectamine TM 2000 (Invitrogen), according to the manufacturer's instructions, using OptiMEMI (Gibco) to co-transfect adherent cells with ACE integrase (pSI0343) and pCTV927 / Hendra virus sGT1. The ACE integrase consists of an integrase gene amplified from phage lambda DNA but optimized for mammalian expression. At 37°C / 5% CO 2 The culture was incubated with fresh ChK2 adherent medium overnight. The next day, the medium was removed, and the cells were carefully washed with PBS, then ...

Embodiment 3

[0093] Example 3: Protein production of soluble G protein using vaccinia

[0094] To produce the protein, a genetic construct containing a codon-optimized sequence is used to produce a recombinant poxvirus vector (vaccinia virus, WR strain). Then use standard techniques, using tk selection and GUS staining to obtain recombinant poxvirus. Briefly, CV-1 cells were transfected with pMCO2sHeVG fusion or pMCO2sNiVG fusion using calcium phosphate transfection kit (Promega). These monolayers were then infected with the Western Reserve (WR) wild-type strain of vaccinia virus at a multiplicity of infection (MOI) of 0.05 PFU / cell. After 2 days, the cell pellet was collected as a crude recombinant virus stock. In the presence of 25μg / ml 5-bromo-2'-deoxyuridine (BrdU) (Calbiochem), TK - The cells are infected with recombinant crude stock. After 2 hours, the virus was replaced with an EMEM-10 overlay containing 1% low melting point (LMP) agarose (Life Technologies) and 25 μg / ml BrdU. Afte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to Hendra and Nipah immunogenic compositions and methods of use. The invention also relates to methods of distinguishing subjects vaccinated with the immunogenic compositions of the invention from those infected with Hendra and / or Nipah virus.

Description

Technical field [0001] The present invention relates to immunogenic compositions and vaccine compositions containing G glycoprotein from Hendra virus (HeV), and methods of use in horses. The invention also relates to an improved dosing regimen that helps maintain elevated antibody titers for a longer period of time after vaccination. Background technique [0002] Repeated outbreaks of NiV, which cause a large number of human deaths, have recently been problematic (see, for example, Butler (2000) Nature 429, 7). It is also known that HeV can cause death in humans and animals and is closely related to NiV in genetics and immunology. At present, only one vaccine for preventing infection or disease caused by Nipah virus or Hendra virus is known (WO2009 / 117035). Both Nipah virus and Hendra virus are C-class priority pathogens of biological defense concern of the National Institute of Allergy and Infectious Diseases (United States, National Institute of Allergy and Infectious Disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/155
CPCA61K39/12A61K2039/55577C12N2760/18234A61P31/12A61P37/04A61K39/155A61K2039/545A61K2039/525A61K2039/552A61K2039/575C12N7/00C12N2760/18022C12N2760/18034C12N2760/18071C12N2760/18222C12N2760/18271
Inventor N·爱德华兹J·黄M·韦尔林
Owner ZOETIS SERVICE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com